

Arden and Greater East Midlands Commissioning Support Unit in association with
Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

Lincolnshire *PACE* Shorts

Summary of PACEF decisions from April 2016

For further details see *PACE Bulletin* Volume 10; Number 7 (May 2016)

SUMMARY OF PACEF DECISIONS: April 2016 UPDATE

Device, Dressing or Drug	Indication(s)	Traffic Light and <i>Joint Formulary</i> Status
<i>Cetraben</i> lotion (Thornton and Ross)	For the treatment of dry skin conditions and eczema.	GREEN Included in the <i>Lincolnshire Joint Formulary</i> .
<i>Cetraben</i> ointment (Thornton and Ross)	For the treatment of dry skin conditions and eczema.	GREEN Included in the <i>Lincolnshire Joint Formulary</i> .
<i>E45</i> cream (Forum)	For ichthyosis, dermatitis, traumatic dermatitis, dry stages of, eczema, dry psoriasis and dry skin conditions.	GREEN Included in the <i>Lincolnshire Joint Formulary</i> . <i>ZeroCream</i> should be preferred first line.
Etanercept 50mg pre-filled syringe/ pre-filled pens (<i>Benepali</i>) (Biogen Idec Ltd)	<p>For use in combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. For use as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. For the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.</p> <p>For the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate.</p> <p>For the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.</p> <p>For the treatment of adults with severe non-radiographic axial spondyloarthritis who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs).</p> <p>For the treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy,</p>	RED Preferred lower cost alternative to etanercept (<i>Enbrel</i>) Approved for inclusion in <i>Lincolnshire Joint Formulary</i> .

	including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA) (
Ezetimibe 10mg tablets(<i>Ezetrol</i>) (MSD)	<p>In combination with statins as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia who are not appropriately controlled with a statin alone.</p> <p>Ezetimibe monotherapy is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia in whom a statin is considered inappropriate or is not tolerated.</p> <p>To reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) when added to ongoing statin therapy or initiated concomitantly with a statin.</p> <p>Co-administered with a statin, ezetimibe is indicated as adjunctive therapy to diet for use in patients with homozygous familial hypercholesterolaemia. Patients may also receive adjunctive treatments (e.g., LDL apheresis).</p> <p>Ezetimibe is indicated as adjunctive therapy to diet for use in patients with homozygous familial sitosterolaemia.</p>	GREEN subject to prescribing guidance. Included in the <i>Lincolnshire Joint Formulary</i> .
<i>Fresubin Thickened Stage 1</i> , 200ml bottle (Fresenius-Kabi)	Nutritional supplement for dysphagia or disease-related malnutrition	AMBER subject to assessment by a Speech and Language Therapist or a Dysphagia Trained Nurse. Approved for inclusion in <i>Lincolnshire Joint Formulary</i> .
<i>Fresubin Thickened Stage 2</i> , 200ml bottle (Fresenius-Kabi)	Nutritional supplement for dysphagia or disease-related malnutrition	AMBER subject to assessment by a Speech and Language Therapist or a Dysphagia Trained Nurse. Approved for inclusion in <i>Lincolnshire Joint Formulary</i> .
Linezolid 600mg tablets (<i>Zyvox Tablets</i>) (Pfizer)	For nosocomial pneumonia, community acquired pneumonia and complicated skin and soft tissue infections in a hospital environment	RED Included in the <i>Lincolnshire Joint Formulary</i> .
Linezolid oral suspension 100mg in 5ml (<i>Zyvox Oral Suspension</i>) (Pfizer)	For nosocomial pneumonia, community acquired pneumonia and complicated skin and soft tissue infections in a hospital environment	RED Included in the <i>Lincolnshire Joint Formulary</i> .
Mexiletine 100mg and 200mg capsules	For the treatment of life-threatening ventricular arrhythmias	AMBER without shared care. Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Ruxolitinib (<i>Jakavi</i>) 5mg, 10mg, 15mg and 20mg tablets (Novartis Pharmaceuticals Ltd)	For the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.	RED Included in the <i>Lincolnshire Joint Formulary</i> .
Simvastatin/ezetimibe (<i>Inegy</i>) 20mg/10mg, 40mg/10mg and 80mg/10mg tablets (MSD)	To reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS),	RED-RED Not included in the <i>Lincolnshire Joint Formulary</i> .

	<p>either previously treated with a statin or not.</p> <p>As adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate: (i.e. in patients not appropriately controlled with a statin alone or patients already treated with a statin and ezetimibe)</p> <p>As adjunctive therapy to diet for use in patients with homozygous familial hypercholesterolaemia. Patients may also receive adjunctive treatments (e.g., low-density lipoprotein [LDL] apheresis).</p>	
Tedizolid 200mg powder for solution for infusion (<i>Sivextro</i>) (Merck Sharp and Dohme)	For the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.	RED Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Tedizolid 200mg tablet (<i>Sivextro</i>) (Merck Sharp and Dohme)	For the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.	RED Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Temozolomide (<i>Temodal</i>) 5mg, 20mg, 100mg, 140mg, 180mg and 250mg tablets (Merck, Sharp and Dohme Ltd)	For the treatment of adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.	RED Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
ZeroAQS cream (T&R Derma)	For flaking dry skin conditions.	GREEN first line alternative to Aqueous Cream. Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Zerobase cream (T&R Derma)	For the treatment of red, inflamed, dry skin and as a diluent for topical steroids.	GREEN first line alternative to <i>Diprobase</i> . Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
ZeroCream cream (T&R Derma)	For ichthyosis, dermatitis, sunburn, eczema, psoriasis, dry or chapped skin.	GREEN first line alternative to E45 cream. Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Zeroderm ointment (T&R Derma)	For the treatment of dry skin in eczema and psoriasis and in other dry skin conditions.	GREEN first line alternative to <i>Hydromol Ointment</i> . Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Zerodouble gel (T&R Derma)	For the treatment of eczema, psoriasis, dermatitis, ichthyosis, elderly pruritus and other dry skin conditions	GREEN first line alternative to <i>Doublebase gel</i> . Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Zerolatum Bath Emollient (T&R Derma)	For dermatitis, senile pruritis, ichthyosis and related dry skin disorders.	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .

RED-RED: This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

RED: This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

AMBER: This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

GREEN: This signifies a product that is **approved for initiation in either primary or secondary care.**

What's new this month?

- **Ezetimibe guidance remains unchanged after NICE publish an updated Technology Appraisal on the use of ezetimibe in primary heterozygous-familial and non-familial hypercholesterolaemia**

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Sandra France on sandra.france@ardengemcsu.nhs.uk.

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at www.lincolnshirejointformulary.nhs.uk

THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION